Showing results (141-150 of 215) with videos related to
Sort By:
Pageof 22
The Oncologist|July 27, 2014
European perspective on multiple myeloma treatment strategies in 2014Heinz Ludwig, Pieter Sonneveld, Faith Davies, et al.Clinical Lymphoma, Myeloma & Leukemia|January 8, 2013
Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomibJan Smetana, Kristina Berankova, Romana Zaoralova, et al.Seminars in Hematology|May 29, 2025
Report of Consensus Panel 3 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with high-risk diseasePrashant Kapoor, Meletios A Dimopoulos, Stephen M Ansell, et al.Annals of Hematology|April 3, 2020
Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myelomaEvangelos Terpos, Karthik Ramasamy, Nadjoua Maouche, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2012
Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myelomaHeinz Ludwig, Luisa Viterbo, Richard Greil, et al.Blood Cancer Journal|May 8, 2023
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 studyThomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, et al.Lancet (London, England)|June 7, 2021
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trialPhilippe Moreau, Meletios-Athanasios Dimopoulos, Joseph Mikhael, et al.The Lancet. Haematology|July 27, 2024
Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trialKwee Yong, Thomas Martin, Meletios-Athanasios Dimopoulos, et al.Leukemia Research|July 13, 2013
10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma GroupJiri Minarik, Viera Sandecka, Vladimir Maisnar, et al.Haematologica|March 25, 2014
The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma NetworkNiels W C J van de Donk, Antonio Palumbo, Hans Erik Johnsen, et al.Pageof 22